Stock 9995 REMEGEN CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News RemeGen Co., Ltd.

Equities

9995

CNE1000048G6

Delayed Hong Kong S.E.
Other stock markets
 07:21:25 02/05/2024 am IST 		5-day change 1st Jan Change
28 HKD +0.18% Intraday chart for RemeGen Co., Ltd. -6.67% -25.23%
26/04 RemeGen Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04/04 Remegen Gets US FDA Fast Track Designation for Primary Sjögren's Syndrome Medication MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
RemeGen Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Remegen Gets US FDA Fast Track Designation for Primary Sjögren's Syndrome Medication
MT
Remegen Co., Ltd. Announces FDA Grants Telitacicept Fast Track designation for Treatment of pSS
CI
Remegen Plans A-Share Private Placement to Fund New Drug Development Project
CI
RemeGen Co., Ltd. announced that it expects to receive CNY 2.549999941 billion in funding
CI
RemeGen Co., Ltd.(XSSC:688331) added to FTSE All-World Index
CI
RemeGen Co. Ltd. Presents Oral Presentation on Evaluation of its Proprietary Disitamab Vedotin for Cervical Cancer At ESGO 2024
CI
RemeGen's 2023 Net Loss Widens; Revenue Jumps 40%
MT
RemeGen Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
RemeGen's Loss to Widen in 2023
MT
RemeGen Co., Ltd. Provides Earnings Guidance for the Period from January 1, 2023 to December 31, 2023
CI
Biocytogen Launches RenBiologics, a Sub-Brand Focused on Out-Licensing Fully Human Antibodies for Therapeutic Development
AQ
RemeGen Buys Back HK$12 Million Worth of Hong Kong Shares
MT
RemeGen Denies Rumors of Tight Cash Flow, Funding Hurdles
MT
RemeGen's Rc88 Obtains FDA Fast Track Designation, Heralds New Hope for Ovarian Cancer Patients
CI
RemeGen Co., Ltd.'s Pioneering RC88 Receives IND Approval from US FDA for Platinum-Resistant Recurrent Ovarian Cancer Treatment
CI
RemeGen Gets Full Approval for Telitacicept
MT
RemeGen Co., Ltd. Announces the Full Approval of. Telitacicept for. Systemic Lupus erythematosus by NMPA
CI
RemeGen to Hike Annual Caps for Services Agreements
MT
RemeGen Co., Ltd. to Present telitacicept Phase III Clinical Trial Results for Rheumatoid Arthritis Patients in A Late-Breaking Abstract Oral Presentation Session At the American College of Rheumatology
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 9995 Stock
  4. News RemeGen Co., Ltd.